Risk factors for hepatic failure after transarterial chemoembolization in patients with hepatocellular carcinoma: a systematic review and meta-analysis
Issued Date
2025-01-01
Resource Type
ISSN
0954691X
eISSN
14735687
Scopus ID
2-s2.0-105029630837
Pubmed ID
41604560
Journal Title
European Journal of Gastroenterology and Hepatology
Volume
Publish Ahead of Print
Rights Holder(s)
SCOPUS
Bibliographic Citation
European Journal of Gastroenterology and Hepatology Vol.Publish Ahead of Print (2025)
Suggested Citation
Prasitsumrit V., Thiravetyan B., Sodsri T., Thongpiya J., Puyati W., Charoenngam N. Risk factors for hepatic failure after transarterial chemoembolization in patients with hepatocellular carcinoma: a systematic review and meta-analysis. European Journal of Gastroenterology and Hepatology Vol.Publish Ahead of Print (2025). doi:10.1097/MEG.0000000000003137 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/115080
Title
Risk factors for hepatic failure after transarterial chemoembolization in patients with hepatocellular carcinoma: a systematic review and meta-analysis
Corresponding Author(s)
Other Contributor(s)
Abstract
Hepatic failure is a potentially fatal complication in hepatocellular carcinoma (HCC) patients undergoing transarterial chemoembolization (TACE). However, there is a lack of clear predictive factors for hepatic failure after TACE in HCC patients. This study aimed to identify all available data and determine the risk factors associated with hepatic failure after TACE in HCC patients. A systematic review and meta-analysis included 9 studies with a total of 1654 patients. The results showed that factors significantly associated with hepatic failure after TACE included female sex [odds ratio (OR) = 1.38, 95% confidence interval (CI) 1.09–1.75], low albumin [mean difference (MD) = −0.34, 95% CI: −0.61 to −0.07] and platelet (MD = −15.84, 95% CI: −23.62 to −8.05), high total bilirubin (MD = 0.64, 95% CI: 0.24–1.04), aspartate aminotransferase (MD = 25.45, 95% CI: 3.88–47.01), alanine aminotransferase (MD = 8.79, 95% CI: 0.15–17.42), international normalized ratio (MD = 0.18, 95% CI: 0.03–0.32), alpha-fetoprotein (MD = 74.05, 95% CI: 64.12–83.99), Model for End-Stage Liver Disease (MD = 3.41, 95% CI: 0.95–5.87), and high Child-Turcotte-Pugh class (OR = 4.66, 95% CI: 1.52–14.28), larger tumor size (MD = 7.75, 95% CI: 6.87–8.63), presence of portal vein thrombosis (OR = 1.78, 95% CI: 1.19–2.67), and high indocyanine green retention test after 15 min (ICG-R15 test) (MD = 16.75, 95% CI: 13.16–20.34). These findings may help clinicians with treatment planning, patient counseling, and postprocedural monitoring.